Ophthalmic moxifloxacin (Vigamox) and gatifloxacin (Zymar).
D000328:Adult; D001372:Aza Compounds / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000077734:Gatifloxacin; D006801:Humans; D000077266:Moxifloxacin; D009883:Ophthalmic Solutions; D011247:Pregnancy; D011804:Quinolines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D001372:Aza Compounds; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin